Silverstone D E, Brint S F, Olander K W, Taylor R B, McCarty G R, deFaller J M, Burk L L
Department of Ophthalmology and Visual Sciences, Yale University School of Medicine, New Haven, Connecticut.
Am J Ophthalmol. 1992 Apr 15;113(4):401-5. doi: 10.1016/s0002-9394(14)76162-8.
We evaluated the prophylactic effect of 1% apraclonidine HCl in controlling the increase in intraocular pressure after Nd:YAG posterior capsulotomy in a large, multicenter double-masked clinical trial. One hundred sixty-four patients were enrolled into the apraclonidine-treated group, and 165 into the vehicle-treated group. The incidence of increase in intraocular pressure (greater than 5 mm Hg) in the apraclonidine-treated group (7%, 11 of 163 patients) was significantly less than that in the vehicle-treated group (39%, 64 of 164 patients). Similarly, the mean maximal change in intraocular pressure in the apraclonidine-treated group (1.3-mm Hg decrease) was significantly different from the increase in the vehicle-treated group (5.3-mm Hg increase). Few adverse reactions were observed. The risk for significant loss of visual function after Nd:YAG laser posterior capsulotomy, combined with the efficacy and relative safety of prophylactic apraclonidine, suggest its addition to the treatment armamentarium.
在一项大型多中心双盲临床试验中，我们评估了1%盐酸阿可乐定在控制钕:钇铝石榴石激光后囊切开术后眼压升高方面的预防效果。164例患者被纳入阿可乐定治疗组，165例患者被纳入赋形剂治疗组。阿可乐定治疗组眼压升高（大于5 mmHg）的发生率（7%，163例患者中的11例）显著低于赋形剂治疗组（39%，164例患者中的64例）。同样，阿可乐定治疗组眼压的平均最大变化（降低1.3 mmHg）与赋形剂治疗组的升高（升高5.3 mmHg）有显著差异。观察到的不良反应很少。钕:钇铝石榴石激光后囊切开术后发生严重视觉功能丧失的风险，再加上预防性使用阿可乐定的疗效和相对安全性，表明应将其纳入治疗手段。
